98%
921
2 minutes
20
Background: In vitro fertilisation (IVF) 'add-ons' are extra (non-essential) procedures, techniques or medicines, which usually claim to increase the chance of a successful IVF outcome. Use of IVF add-ons is believed to be widespread in many settings; however, information about add-on availability in Australasia is lacking.
Aims: To understand which add-ons are advertised on Australasian IVF clinic websites, and what is the evidence for their benefit.
Materials And Methods: A systematic assessment of website content was undertaken between December 2019-April 2020, capturing IVF add-ons advertised, including costs, claims of benefit, statements of risk or limitations, and evidence of effectiveness for improving live birth and pregnancy. A literature review assessed the strength and quality of evidence for each add-on.
Results: Of the 40 included IVF clinics websites, 31 (78%) listed one or more IVF add-ons. A total of 21 different add-ons or add-on groups were identified, the most common being preimplantation genetic testing for aneuploidies (offered by 63% of clinics), time-lapse systems (33%) and assisted hatching (28%). In most cases (77%), descriptions of the IVF add-ons were accompanied by claims of benefit. Most claims (90%) were not quantified and very few referenced scientific publications to support the claims (9.8%). None of the add-ons were supported by high-quality evidence of benefit for pregnancy or live birth rates. The cost of IVF add-ons varied from $0 to $3700 (AUD/NZD).
Conclusions: There is widespread advertising of add-ons on IVF clinic websites, which report benefits for add-ons that are not supported by high-quality evidence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ajo.13321 | DOI Listing |
Eur J Obstet Gynecol Reprod Biol
July 2025
IVIRMA Global Research Alliance, IVI, via Dante 15, 40125, Bologna, Italy.
Objective: To critically appraise IVF add-ons, based on current evidence, international recommendations, and expert consensus from SIFES-MR.
Study Design: Consensus developed by a multidisciplinary panel of Italian reproductive medicine experts over two years, based on clinical expertise, revision of guidelines from ESHRE, HFEA, ISAR, and ASRM, and additional more recent references retrieved from the literature. A list of statements was produced and agreed upon the panel using a Delphi consensus workflow.
Reprod Biomed Online
August 2025
Reproductive Services Unit, The Royal Women's Hospital, Melbourne, Victoria, Australia.; Genea Fertility Melbourne City, Melbourne, Victoria, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
In the dynamic field of reproductive medicine, the introduction of new technologies often follows a modified Gartner Hype Cycle, characterized by initial enthusiasm, unmet inflated expectations and eventual disillusionment. This paper explores how the Dunning-Kruger effect, where individuals overestimate their knowledge and competence, contributes to the Gartner Hype Cycle in reproductive medicine. By examining the history of the endometrial scratch, the paper illustrates the negative impact of prematurely adopted innovations.
View Article and Find Full Text PDFHum Reprod Open
March 2025
Center for Human Reproduction (CHR), New York, NY, USA.
Embryo selection (ES) during IVF is expected to select the 'best' embryo(s) from among a cycle's embryo cohort and has been a core concept of IVF for over 40 years. However, among 36 492 articles on ES in a recent PubMed search, we were unable to locate even a single one questioning the concept that, beyond standard oocyte and embryo morphology, ES has remained an unproven hypothesis. In unselected patient populations, attempts at ES have universally, indeed, failed to improve cumulative pregnancy and live birth rates.
View Article and Find Full Text PDFHum Fertil (Camb)
December 2025
Centre for Biostatistics, Manchester Academic Health Science Centre, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK.
This study presents the findings from a UK-based survey exploring fertility treatment add-ons, treatment costs, and information transparency. The online survey, distributed via social media, targeted current and prospective IVF patients, yielding 304 eligible responses. Results indicate an increase in the use of fertility treatment add-ons compared to previous data.
View Article and Find Full Text PDFHum Reprod
February 2025
Westmead Fertility Centre, Institute of Reproductive Medicine, University of Sydney, Westmead, NSW, Australia.